Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509067 | 0.89 | CYP2A6 (0.52) | CYP2A6LOXL2RAB9ATSHRHSD17B10 | |
| SCHEMBL1534961 | 0.84 | CYP2A6 (0.59) | CYP2A6LOXL2RAB9ATSHRHSD17B10 | |
| SCHEMBL3401155 | 0.83 | LOXL2 (0.56) | CYP2A6LOXL2RAB9ATSHRMAOB | |
| SCHEMBL648284 | 0.83 | TSHR (0.43) | TSHRNPC1L3MBTL1ALDH1A1CA2 | |
| SCHEMBL1680712 | 0.83 | CYP2A6 (0.53) | CYP2A6LOXL2RAB9ATSHRHSD17B10 | |
| SCHEMBL26582580 | 0.81 | HDAC8 (0.33) | CYP2A6TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL23014982 | 0.81 | LOXL2 (0.50) | CYP2A6LOXL2RAB9AMAOBNPC1 | |
| SCHEMBL4223936 | 0.81 | CHRM3 (0.48) | CYP2A6LOXL2RAB9AHSD17B10MAOB | |
| SCHEMBL1427951 | 0.81 | MAOB (0.46) | CYP2A6LOXL2RAB9AMAOBNPC1 | |
| SCHEMBL24942155 | 0.80 | HRH3 (0.47) | CYP2A6LOXL2RAB9ATSHRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. | 2022-09-15 | — | — | US | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | TK1, TTR, TALDO1 | CYP2A6 1880/4885LOXL2 2901/4885RAB9A 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.